 |
|
|
| |
No clinically significant interaction between the investigational HCV protease inhibitor simeprevir (TMC435) and the immunosuppressive agents cyclosporine and tacrolimus
|
| |
| |
Reported by Jules Levin
AASLD Nov 2012 Boston
S Ouwerkerk-Mahadevan,1 A Simion,2 S Mortier,2
M Peeters,2 M Beumont-Mauviel2
1Janssen Research and Development, Beerse, Belgium; 2Janssen Infectious Diseases, Beerse, Belgium
|
| |
|
|
|
|
|
